At the end of any summer, we brace ourselves — for back to school, returning to work and even for Christmas plans.
However, this year, the reality bump is like no other.
As the COVID-19 pandemic continues to reverberate globally, there is no doubt that we must be ready to face a long road ahead, certainly beyond the end of this year.
The fact that a vaccine, alongside effective treatments, is our only true exit strategy remains unchanged. The speed and scale of vaccine development have been remarkable, but it is important to avoid false hope.
I am optimistic that we will soon see results from the first vaccines coming through late-stage clinical trials.
However, we must temper this optimism, this talk of the perfect vaccine “just around the corner” or the idea that it will be a complete and immediate solution.
Over the summer, the UK vaccine task force has done an impressive job of securing access to a broad portfolio of potential COVID-19 vaccines, but I worry that, beyond the task force, too much hype is being applied to the first vaccines and in some countries too much focus on a political agenda and domestic provision.
There should be no place for notions of vaccine nationalism, with nations posturing that “their” vaccine will cross the finish line first and be fully deployed by Christmas or for a political moment.
The “first” vaccine, or even the first generation of vaccines, will most likely not be perfect; we need to be pragmatic and transparent on that front. The reality is that with these vaccines, we will be taking small steps to return to a sense of normality.
Plenty is attached to the word vaccine. When we hear it, we think of one of the greatest advances in human health, one that eliminates smallpox and saves millions every year from polio and tetanus, from HPV and the flu.
However, the first generation of COVID-19 vaccines will probably be only partially effective.
They might not be completely effective in all ages or appropriate in all health systems. It is very possible that they might provide immunity only for a limited period, even as short as 12 to 18 months.
This might not be what we are used to from a vaccine, but there is no doubt that the first effective vaccines, even imperfect ones, can have a major impact and be a precious commodity.
Urgency must not be misunderstood; accelerating vaccine development must not mean compromising safety. Transparent, rigorous assessment by independent regulatory bodies without political interference is non-negotiable.
Trust is our most important tool in public health and we must do everything we can to avoid putting that in doubt. It cannot be bought on short-term promises.
Already, there are worrying signs of diminishing trust in potential COVID-19 vaccines.
Polls suggest that in countries with some of the highest global case numbers, such as the US, there could be low uptake of any COVID-19 vaccine, no matter how effective.
This must not become a polarized political issue; public health is too important.
Most importantly, fair access to any vaccine must be addressed. No matter where the first vaccines originate, they must initially reach priority groups worldwide, particularly frontline healthcare workers and the most vulnerable.
Global cooperation is key to advancing these vaccines and restarting the economy.
If large parts of the world remain shut down because of the selfish hoarding of initial supplies by richer nations, we all suffer for it.
However, it is not enough to simply promise support for fair, global allocation. More nations must act with urgency and buy into a collective and pooled approach to vaccine access, all governments being clear that they will buy doses only for the most at risk in their populations.
The US not joining the vital COVID-19 Vaccines Global Access Facility (COVAX), which aims to ensure equal access to affordable vaccines, is disappointing.
It is more imperative than ever that those in stronger positions, with considerable resources, lead by example in fair allocation.
The UK has maneuvered itself into such a leading position. It has options on a 340 million-dose stockpile, the highest access per capita of any country. Yet only 20 to 30 percent of the UK population will require access to a vaccine in the first few months.
The UK’s position could be even stronger through firm commitments to pooling surplus doses through COVAX.
The European Commission has also shown important leadership and has committed 400 million euros (US$470 million), but it too is in a strong position to do more.
Such enlightened global leadership is badly needed at this time of crisis.
As we move through autumn and winter, we will see an increase in community transmission. Without urgent action to stop the current increased community transmission among young adults leading to transmission in hospitals and in social care, and thereby severe illness and deaths in vulnerable people, we will be facing a chaotic stop-start winter for schools and businesses.
We have to do everything possible to avoid this.
The first vaccine might not be a magic bullet that sends us back to normal in a matter of months. However, by using doses wisely on the people who most need them — and doing this alongside truthful, considered public health messaging that does not deal in false expectations — we will be in a strong position to avoid a repeat of the start of this year.
Jeremy Farrar is director of the Wellcome Trust.
US President Donald Trump last week told reporters that he had signed about 12 letters to US trading partners, which were set to be sent out yesterday, levying unilateral tariff rates of up to 70 percent from Aug. 1. However, Trump did not say which countries the letters would be sent to, nor did he discuss the specific tariff rates, reports said. The news of the tariff letters came as Washington and Hanoi reached a trade deal earlier last week to cut tariffs on Vietnamese exports to the US to 20 percent from 46 percent, making it the first Asian country
Life as we know it will probably not come to an end in Japan this weekend, but what if it does? That is the question consuming a disaster-prone country ahead of a widely spread prediction of disaster that one comic book suggests would occur tomorrow. The Future I Saw, a manga by Ryo Tatsuki about her purported ability to see the future in dreams, was first published in 1999. It would have faded into obscurity, but for the mention of a tsunami and the cover that read “Major disaster in March 2011.” Years later, when the most powerful earthquake ever
Chinese intimidation of Taiwan has entered a chilling new phase: bolder, more multifaceted and unconstrained by diplomatic norms. For years, Taiwan has weathered economic coercion, military threats, diplomatic isolation, political interference, espionage and disinformation, but the direct targeting of elected leaders abroad signals an alarming escalation in Beijing’s campaign of hostility. Czech military intelligence recently uncovered a plot that reads like fiction, but is all too real. Chinese diplomats and civil secret service in Prague had planned to ram the motorcade of then-vice president-elect Hsiao Bi-khim (蕭美琴) and physically assault her during her visit to the Czech Republic in March last
As things heated up in the Middle East in early June, some in the Pentagon resisted American involvement in the Israel-Iran war because it would divert American attention and resources from the real challenge: China. This was exactly wrong. Rather, bombing Iran was the best thing that could have happened for America’s Asia policy. When it came to dealing with the Iranian nuclear program, “all options are on the table” had become an American mantra over the past two decades. But the more often US administration officials insisted that military force was in the cards, the less anyone believed it. After
RSS